Germ Cell Tumor
Associated Genetic Biomarkers
NCI Definition: A benign or malignant, gonadal or extragonadal neoplasm that originates from germ cells. Representative examples include teratoma, seminoma, embryonal carcinoma, and yolk sac tumor. 
Germ cell tumors most frequently harbor alterations in KRAS, CDKN1B, CCND2, ETV6, and RAD52 .
CDKN1B Amplification, KRAS Amplification, CCND2 Amplification, ETV6 Amplification, and RAD52 Amplification are the most common alterations in germ cell tumor .
There are 14 clinical trials for germ cell tumor, of which 10 are open and 4 are completed or closed. Of the trials that contain germ cell tumor as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 10 are phase 2 (6 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).
BRAF and RB1 are the most frequent gene inclusion criteria for germ cell tumor clinical trials .
Asp1650, g207, and azacitidine are the most common interventions in germ cell tumor clinical trials.
Significant Genes in Germ Cell Tumor
CCNE2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCNE2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) .
CDK2 is an inclusion eligibility criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.